
CNTA Stock Forecast & Price Target
CNTA Analyst Ratings
Bulls say
Centessa Pharmaceuticals PLC is positioned favorably due to its robust cash reserves of approximately $405 million, which are projected to sustain operations into mid-2027, allowing for continued development of its promising pipeline. The company's lead asset, ORX750, is anticipated to demonstrate best-in-class efficacy in treating narcolepsy and is supported by positive preliminary outcomes and the potential for enhanced dose-response profiles, which could create substantial differentiation from competitors. Additionally, the estimated sales potential for ORX750 in the narcolepsy market, projected at around $3.6 billion, underscores significant upside potential as the market for orexin agonists expands, fostering optimism among investors.
Bears say
Centessa Pharmaceuticals faces significant commercial and competitive risks due to market pressures from other development assets, which may hinder the potential of its therapeutic offerings. The company is also grappling with high non-responder rates and waning efficacy in key programs, raising concerns about both the effectiveness of its treatments and the potential for optimal dosing strategies. Furthermore, the conservative assessment of market penetration suggests that the stock may be overly optimistic given the challenges outlined, indicating a substantial disconnect between current valuation and future growth prospects.
This aggregate rating is based on analysts' research of Centessa Pharmaceuticals PLC and is not a guaranteed prediction by Public.com or investment advice.
CNTA Analyst Forecast & Price Prediction
Start investing in CNTA
Order type
Buy in
Order amount
Est. shares
0 shares